Product logins

Find logins to all Clarivate products below.


Venous Thromboembolism – Epidemiology – Epidemiology Dashboard

Clarivate Epidemiology’s coverage of VTE comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the diagnosed events of VTE for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the mature markets and Europe, and 10 years for the other countries we cover.

All forecast data are available on Clarivate’s Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

Clarivate Epidemiology’s VTE forecast answers the following questions:

  • How will changes in the levels of exposure to known risk or protective factors affect the number of people living with a diagnosis of VTE and the number of new diagnoses of VTE?
  • Of all people diagnosed with VTE, how many in each country across the major mature pharmaceutical markets are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of VTE over the forecast period?

In addition to the total number of cases for each forecast year, Clarivate Epidemiology provides at least 10 years of forecast data for the following VTE subpopulations:

  • Top-line epidemiology – Diagnosed VTE events.
  • Key Populations – Diagnosed DVT events.
  • Key Populations – Diagnosed PE events.
  • Diagnosed VTE events by etiology.
  • Diagnosed VTE events by recurrence.
  • Diagnosed DVT events by treatment scheme.
  • Diagnosed PE events by treatment scheme.

Note: Coverage may vary by country.

Related Market Assessment Reports

Report
Alopecia – Current Treatment – Treatment Algorithms: Claims Data Analysis – Alopecia Areata (US)
Alopecia areata (AA) is an autoimmune condition in which the immune-mediated damage to hair follicles results in patchy or extensive hair loss. AA treatment is evolving rapidly as dermatologists…
Report
Immune Thrombocytopenic Purpura – Current treatment – Treatment Algorithms: Claims Data Analysis – Immune Thrombocytopenic Purpura (US)
Immune thrombocytopenic purpura (ITP) is an autoimmune disorder characterized by a low platelet count, resulting in an increased risk of bleeding. Current therapies for ITP can be largely divided…
Report
Myasthenia Gravis – Geography Focus: China – China In-Depth: Myasthenia Gravis
China’s myasthenia gravis (MG) market is transitioning from long-standing symptomatic regimens toward a more structured mix of targeted therapies that increasingly shape treatment pathways…
Report
Chronic Urticaria – Current Treatment – Treatment Algorithms: Claims Data Analysis – Chronic Spontaneous Urticaria (US)
The treatment landscape for chronic spontaneous urticaria (CSU) remains largely driven by oral therapies, including approved antihistamines and off-label agents such as DMARDs and…
Report
Psoriatic Arthritis – Unmet Need – Unmet Need – Psoriatic Arthritis (US/EU)
The psoriatic arthritis (PsA) therapy market is on a growth trajectory, fueled by the disease’s increasing prevalence, innovative treatment options, and heightened patient awareness. TNF-alpha…